Quince Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a clinical-stage biotechnology company that underwent a major strategic transformation in mid-2026. Historically focused on its autologous intracellular drug encapsulation (AIDE) technology platform and its lead asset eDSP (which failed its Phase 3 NEAT clinical trial in January 2026, leading to the cessation of eDSP development), Quince pivoted to rare pulmonary diseases. On May 18, 2026, Quince completed the acquisition of Orphai Therapeutics, Inc. in a stock-for-stock merger. This transaction brought Orphai's lead program, LAM-001—a proprietary, once-daily inhaled formulation of sirolimus (rapamycin) targeting the mTOR pathway—into Quince's pipeline. LAM-001 is being developed to treat multiple rare pulmonary diseases, including bronchiolitis obliterans syndrome (BOS), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and sarcoidosis-associated pulmonary hypertension (SAPH).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the Phase 3 NEAT trial failure of eDSP in Ataxia-Telangiectasia in January 2026, Quince discontinued all eDSP development activities and pivoted its corporate strategy to focus on rare pulmonary diseases by acquiring Orphai Therapeutics and its lead asset LAM-001.
Expected impact: Replaces the failed lead asset with a clinical-stage inhaled rapamycin program (LAM-001) targeting three rare pulmonary indications (PH-ILD, BOS, and SAPH) with clinical milestones mapped through 2028.
Quince engaged LifeSci Capital to assist in restructuring its liabilities and evaluating strategic alternatives. As part of this effort, the company settled approximately $16.4 million of outstanding debt.
Expected impact: Cleaned up the balance sheet and reduced liabilities, facilitating the subsequent merger with Orphai Therapeutics and the major PIPE financing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Orphai's lead clinical-stage asset, LAM-001 (an inhaled formulation of rapamycin/sirolimus), to pivot Quince's pipeline toward rare pulmonary diseases after the Phase 3 failure of its previous lead asset eDSP.
Financial impact: Structured as an all-stock transaction where Orphai equity holders received 3,258,517 Quince common shares and 67,101.235 Series C preferred shares (convertible to 67.1 million common shares), plus options and replacement warrants. Legacy Quince holders retain approximately 6.9% of the combined company on a fully diluted basis.
Strategic Partnerships
Formed to support the commercial development and launch of eDSP in the U.S. by leveraging Option Care Health's national network of specialty pharmacies and ambulatory infusion suites.
Terms: Terms not fully disclosed; structured as a fee-for-service specialty infusion provider agreement.